<html><body><document>
<type>S-3
<sequence>1
<filename>d499409ds3.htm
<description>FORM S-3
<text>
<title>Form S-3</title>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>As filed with the Securities and Exchange Commission on November&#160;30, 2017 </b></p>
<p align="right" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </b></p>
<p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p align="center" style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>UNITED STATES </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b>Washington, D.C. 20549 </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>FORM <font style="white-space:nowrap">S-3</font> </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>REGISTRATION STATEMENT </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b><i>UNDER </i></b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b><i>THE
SECURITIES ACT OF 1933 </i></b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman"><b>AVEO PHARMACEUTICALS, INC. </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>(Exact name of registrant as specified in its charter) </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" width="100%">
<tr>
<td width="49%"></td>
<td valign="bottom" width="2%"></td>
<td width="47%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td align="center" valign="top"><b>Delaware</b></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top"><b><font style="white-space:nowrap">04-3581650</font></b></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" valign="top"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>(State or other jurisdiction of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>incorporation or organization)</b></p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>(I.R.S. Employer</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Identification Number)</b></p></td></tr>
</table> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>One Broadway, 14th Floor </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Cambridge, Massachusetts 02142 </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>(617) <font style="white-space:nowrap">588-1960</font> </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </b></p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Matthew Dallas </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Chief
Financial Officer </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>AVEO Pharmaceuticals, Inc. </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>One Broadway, 14th Floor </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Cambridge, Massachusetts 02142 </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>(617) <font style="white-space:nowrap">588-1960</font> </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) </b></p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><i>Copy to: </i></b></p> <p align="center" style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Steven
D. Singer, Esq. </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Cynthia T. Mazareas, Esq. </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Wilmer Cutler Pickering Hale and Dorr LLP </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>60 State Street </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>Boston,
Massachusetts 02109 </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>(617) <font style="white-space:nowrap">526-6000</font> </b></p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><b>Approximate date of commencement of proposed sale to the public</b>: From time to time after this registration statement becomes effective.
</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box.&#160;&#160;&#9744; </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#160;&#160;&#9746; </p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this
Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#160;&#160;&#9744; </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment
thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&#160;&#160;&#9744; </p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D filed to register additional securities or
additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#160;&#160;&#9744; </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a <font style="white-space:nowrap">non-accelerated</font> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <font style="white-space:nowrap">12b-2</font> of the Exchange Act.<sup style="font-size:85%; vertical-align:top"> </sup> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="19%"></td>
<td valign="bottom" width="1%"></td>
<td width="52%"></td>
<td valign="bottom" width="1%"></td>
<td width="24%"></td>
<td valign="bottom" width="1%"></td>
<td width="2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom">Large&#160;accelerated&#160;filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Accelerated&#160;filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9746;</td></tr>
<tr style="font-size:1pt">
<td height="5"></td>
<td colspan="2" height="5"></td>
<td colspan="2" height="5"></td>
<td colspan="2" height="5"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom">Non-accelerated filer</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;&#160;&#160;(Do not check if a smaller reporting company)</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">Smaller&#160;reporting&#160;company</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td height="5"></td>
<td colspan="2" height="5"></td>
<td colspan="2" height="5"></td>
<td colspan="2" height="5"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom"></td>
<td valign="bottom">&#160;&#160;</td>
<td nowrap="" valign="bottom">Emerging&#160;growth&#160;company</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#9744;</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;&#160;&#9744; </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>CALCULATION OF REGISTRATION FEE </b></p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="46%"></td>
<td valign="bottom" width="1%"></td>
<td width="10%"></td>
<td valign="bottom" width="1%"></td>
<td width="10%"></td>
<td valign="bottom" width="1%"></td>
<td width="12%"></td>
<td valign="bottom" width="1%"></td>
<td width="14%"></td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Title of Each Class&#160;of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Securities to be Registered(1)</b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Amount</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>to be</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Registered(1)</b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Proposed</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Maximum</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Offering&#160;Price</b></p> <p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Per
Unit(1)</b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Proposed</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Maximum</b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Aggregate</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Offering&#160;Price(1)</b></p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><b>Amount&#160;of</b></p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><b>Registration&#160;Fee(1)</b></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, par value $0.001 per share</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Stock, par value $0.001 per share</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt Securities</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Units</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-TOP:1px solid #000000" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td style="BORDER-TOP:1px solid #000000" valign="bottom"><font size="1">&#160;</font></td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom">$200,000,000</td>
<td style=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000" valign="bottom">&#160;</td>
<td align="center" nowrap="" style="BORDER-TOP:1px solid #000000" valign="bottom">$24,900.00(2)</td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
<tr style="font-size:1px; ">
<td colspan="9" valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(1)</td>
<td align="left" valign="top">Pursuant to Form <font style="white-space:nowrap">S-3</font> General Instruction II.D information is not required to be included. An indeterminate amount of the securities of each identified class is being registered as
may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder as shall have an
aggregate initial offering price not to exceed $200,000,000. Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in
connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other
securities. In addition, the total amount to be registered and the proposed maximum aggregate offering price are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act.
</td></tr></table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(2)</td>
<td align="left" valign="top">Pursuant to Rule 457(p) under the Securities Act, the Registrant hereby offsets the total registration fee due hereunder by $7,872.55, which represents the portion of the registration fee previously paid with respect to
$67,750,000 of unsold securities, or the Unsold Securities, previously registered on the Registrant&#146;s Registration Statement on Form <font style="white-space:nowrap">S-3</font> (File <font style="white-space:nowrap">No.&#160;333-203932)</font>
filed with the Securities and Exchange Commission on May&#160;7, 2015 and declared effective on May&#160;26, 2015, or the Prior Registration Statement. Additionally, as described in the Prior Registration Statement, an additional $9,248.37 is being
applied to offset fees due in connection with this Registration Statement on Form <font style="white-space:nowrap">S-3.</font> Consequently, the filing fee transmitted herewith is $7,779.08. Pursuant to Rule 457(p) under the Securities Act, the
offering of the Unsold Securities under the Prior Registration Statement shall be deemed terminated as of the date of the filing of this registration statement. </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><b>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall
become effective on such date as the Commission acting pursuant to said Section&#160;8(a), may determine. </b></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><font color="#ff4338"><b>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction
where the offer or sale is not permitted. </b></font></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><font color="#ff4338"><b>Subject to completion, dated November&#160;30, 2017 </b></font></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>PROSPECTUS </b></p>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><b>$200,000,000 </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/g499409g70w65.jpg"/>
</p> <p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Preferred Stock </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Debt
Securities </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Warrants </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Units </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
and sell securities from time to time in one or more offerings of up to $200,000,000 in aggregate offering price. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We
will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or amend information
contained in this document. You should read this prospectus and any applicable prospectus supplement before you invest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the
securities, we will name them and describe their compensation in a prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ
Capital Market under the symbol &#147;AVEO.&#148; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><b>Investing in
these securities involves significant risks. See &#147;Risk Factors&#148; included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully
consider before deciding to purchase these securities. </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><b>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>The date of this prospectus
is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017 </b></p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc"></a>TABLE OF CONTENTS </b></p>
<p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="96%"></td>
<td valign="bottom" width="2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_1">ABOUT THIS PROSPECTUS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">1</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_2">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">2</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_3">INCORPORATION BY REFERENCE</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">2</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">4</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_5">ABOUT AVEO PHARMACEUTICALS, INC.</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">5</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_6">CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED
 FIXED CHARGES AND PREFERRED STOCK DIVIDENDS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">6</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_7">USE OF PROCEEDS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">7</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_8">DESCRIPTION OF CAPITAL STOCK</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">8</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_9">DESCRIPTION OF DEBT SECURITIES</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">15</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_10">DESCRIPTION OF WARRANTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">24</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_11">DESCRIPTION OF UNITS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">25</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_12">FORMS OF SECURITIES</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">26</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_13">PLAN OF DISTRIBUTION</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">28</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_14">LEGAL MATTERS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">31</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc499409_15">EXPERTS</a></p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">31</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
</table>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_1"></a>ABOUT THIS PROSPECTUS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, which we refer to as the
&#147;SEC,&#148; utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate
initial offering price of up to $200,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer.
Each time we sell securities, we will provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this
prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading &#147;Where You Can Find More Information&#148; beginning on page&#160;2 of this
prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying
prospectus supplement or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any
circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is
accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#147;we,&#148; &#147;our,&#148; &#147;us,&#148; &#147;AVEO&#148; and
the &#147;Company&#148; refer, collectively, to AVEO Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_2"></a>WHERE YOU CAN FIND MORE INFORMATION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.aveooncology.com/. Our website is not a part of this prospectus and is
not incorporated by reference in this prospectus. You may also read and copy any document we file at the SEC&#146;s Public Reference Room, 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <font style="white-space:nowrap"><font style="white-space:nowrap"><font style="white-space:nowrap">1-800-SEC-0330</font></font></font> for further information on the operation of the Public Reference Room. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the
registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the securities we are offering.
Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should
review the complete document to evaluate these statements. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_3"></a>INCORPORATION BY REFERENCE </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we are incorporating by reference future filings with
the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by
reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File <font style="white-space:nowrap">No.&#160;001-34655)</font> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those
documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the
offering of the securities under the registration statement is terminated or completed: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">Annual Report on Form <font style="white-space:nowrap">10-K</font> for the fiscal year ended December&#160;31, 2016, including the information specifically incorporated by reference into the Annual Report on Form <font style="white-space:nowrap">10-K</font> from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&#160;27, 2017, as amended and supplemented by the Definitive Additional Materials on Schedule 14A that we filed with the SEC on
April&#160;27, 2017 and May&#160;17, 2017; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> for the fiscal quarters ended March&#160;31, 2017, June&#160;30, 2017 and September&#160;30, 2017; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">Current Reports on Form <font style="white-space:nowrap">8-K</font> filed on January&#160;4, 2017, January&#160;5, 2017, January&#160;12, 2017, March&#160;29, 2017, April&#160;12, 2017, May&#160;17, 2017, June&#160;23,
2017, June&#160;27, 2017, August&#160;17, 2017, and November&#160;20, 2017; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">The description of our common stock contained in our Registration Statement on Form <font style="white-space:nowrap">8-A</font> filed on March&#160;9, 2010, including any amendments or reports filed for the purpose of
updating such description. </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the
following address or telephone number: </p> <p align="center" style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AVEO Pharmaceuticals, Inc. </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Broadway, 14th Floor </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02142 </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Investor Relations </p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (617) <font style="white-space:nowrap">588-1960</font> </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_4"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus include &#147;forward-looking statements&#148; within the
meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Exchange Act. These statements are based on current expectations, estimates, forecasts and projections about the industry in
which we operate and the beliefs and assumptions of our management. Words such as &#147;expects,&#148; &#147;anticipates,&#148; &#147;targets,&#148; &#147;goals,&#148; &#147;projects,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; &#147;continues,&#148; and &#147;may&#148; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements
that refer to projections regarding our future financial performance; trends in our business; our capital needs and capital expenditures; our market position and competitive changes in the marketplace for our product candidates and any products; our
ability to innovate new product candidates; our collaborators, licensees and other strategic partners; intellectual property and litigation matters; potential acquisitions and divestitures; key personnel; the effect of new accounting pronouncements
and other characterizations of future events or circumstances are forward-looking statements. You are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions, including: risks
inherent in pharmaceutical research and development, such as adverse results in our clinical development activities and our ability to obtain any necessary financing to conduct our planned activities, decisions made by the U.S. Food and Drug
Administration and other regulatory authorities with respect to the development and commercialization of our drug candidates and those of our collaborators and licensees; risks relating to our ability to obtain, maintain and enforce intellectual
property rights for our drug candidates; risks arising as a result of our dependence on our existing and future strategic partners, and other risk factors that are referenced in the section of any accompanying prospectus supplement entitled
&#147;Risk Factors.&#148; You should also carefully review the risk factors and cautionary statements described in the other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form <font style="white-space:nowrap">10-K,</font> our Quarterly Reports on Form <font style="white-space:nowrap">10-Q</font> and our Current Reports on Form <font style="white-space:nowrap">8-K.</font> We undertake no obligation to revise or update any
forward-looking statements, except to the extent required by law. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_5"></a>ABOUT AVEO PHARMACEUTICALS, INC. </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Company Overview </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. We are focused on seeking to develop and commercialize our lead candidate tivozanib (FOTIVDA<sup style="font-size:85%; vertical-align:top">&#174;</sup>), a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma, or RCC, and other cancers. We
are leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and at progressing our pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
Tivozanib (FOTIVDA<sup style="font-size:85%; vertical-align:top">&#174;</sup>) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway and Iceland. </p>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Company Information </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were incorporated in Delaware on October&#160;19, 2001 as GenPath Pharmaceuticals, Inc. and changed our name to AVEO Pharmaceuticals, Inc. on March&#160;1, 2005. Our principal executive offices are located at One Broadway, 14th Floor, Cambridge,
Massachusetts 02142, and our telephone number is (617) <font style="white-space:nowrap">588-1960.</font> Our website is located at www.aveooncology.com. Information found on, or accessible through, our website is not a part of, and is not
incorporated into, this prospectus, and you should not consider it part of this prospectus. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_6"></a>CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF
</b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our ratio of earnings to fixed charges for each of the periods indicated. You should read this table in
conjunction with the consolidated financial statements and notes incorporated by reference in this prospectus. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" width="100%">
<tr>
<td width="34%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">Nine Months<br/>Ended<br/>September&#160;30,<br/>2017</td>
<td rowspan="2" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="18" valign="bottom">Fiscal Year Ended</td>
<td valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">December&#160;31,<br/>2016</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">December&#160;31,<br/>2015</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">December&#160;31,<br/>2014</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">December&#160;31,<br/>2013</td>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" colspan="2" style="border-bottom:1.00pt solid #000000" valign="bottom">December&#160;31,<br/>2012</td>
<td valign="bottom">&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated ratios of earnings to fixed charges</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td>
<td colspan="4" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consolidated ratios of earnings to combined fixed charges and preferred stock dividends</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">N/A</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of calculating the ratios above, earnings consist of income before income taxes plus fixed
charges. Fixed charges include interest expense, <font style="white-space:nowrap">non-cash</font> interest expense, and an estimate of the interest expense within rental expense. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our earnings were insufficient to cover fixed charges for the periods listed above, and we are unable to disclose a ratio of earnings to fixed
charges or ratio of earnings to combined fixed charges and preferred stock dividends for such periods. The dollar amount in thousands of the deficiency in earnings available for fixed charges for the nine months ended September&#160;30, 2017 and the
fiscal years ended December&#160;31, 2016, 2015, 2014, 2013 and 2012 was approximately $68,423, $26,786, $15,001, $52,739, $107,029 and $114,394, respectively. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_7"></a>USE OF PROCEEDS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless
otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the repayment and refinancing of debt; working capital and capital expenditures; research and development expenses, including clinical trial costs;
general and administrative expenses; and the potential acquisition of, or investment in, companies, technologies, products or assets that complement our business. We have not determined the amount of net proceeds to be used specifically for such
purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_8"></a>DESCRIPTION OF CAPITAL STOCK </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock.
This description is based upon, and is qualified by reference to, our restated certificate of incorporation, as amended, or certificate of incorporation, our second amended and restated <font style="white-space:nowrap">by-laws,</font> or <font style="white-space:nowrap">by-laws,</font> and applicable provisions of Delaware corporate law. You should read our certificate of incorporation and <font style="white-space:nowrap">by-laws,</font> which are filed as exhibits to the registration
statement of which this prospectus forms a part, for the provisions that are important to you. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of
250,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. At our 2017 annual meeting of stockholders, held on June&#160;21, 2017, we received stockholder approval for a
proposed amendment to our certificate of incorporation to effect a reverse stock split of our common stock by a ratio of not less than <font style="white-space:nowrap"><font style="white-space:nowrap">1-for-3</font></font> and not more than <font style="white-space:nowrap"><font style="white-space:nowrap">1-for-15,</font></font> such ratio and the implementation and timing of such reverse stock split to be determined in the discretion of our board of directors provided that the board of
directors must determine to effect the reverse stock split and such amendment must be filed with the Secretary of State of the State of Delaware no later than December&#160;19, 2017. As of November&#160;30, 2017, no such reverse stock split has been
effected. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Common Stock </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Annual Meeting.</i> Annual meetings of our stockholders are held on the date designated in accordance with our <font style="white-space:nowrap">by-laws.</font> Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person or by proxy of the holders of record of a
majority in voting power of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders, unless otherwise prescribed by
statute or by our certificate of incorporation, may be called for any purpose or purposes, by the chairman of our board of directors, our board of directors, or our chief executive officer. Except as may be otherwise provided by applicable law, our
certificate of incorporation or our <font style="white-space:nowrap">by-laws,</font> all elections, other than elections of directors, and all other questions shall be decided by the affirmative vote of the holders of a majority in voting power of
the shares of our stock which are present in person or by proxy and voting affirmatively or negatively on such matter. Except as may be provided by applicable law, our certificate of incorporation or our
<font style="white-space:nowrap">by-laws,</font> each director shall be elected by the vote of the plurality of the votes cast by the stockholders entitled to vote with respect to that director&#146;s election at any meeting for the election of
directors at which a quorum is present. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Voting Rights</i>. Each holder of common stock is entitled to one vote for each share held of
record on all matters to be voted upon by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Dividends</i>. Subject to the rights, powers and preferences of any
outstanding preferred stock, and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the
board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Liquidation, Dissolution and Winding Up</i>. Subject to the rights, powers and preferences of any outstanding
preferred stock, in the event of our liquidation, dissolution or winding up, our net assets will be distributed pro rata to the holders of our common stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Other Rights</i>. Holders of the common stock have no right to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">convert the stock into any other security; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">have the stock redeemed; </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">purchase additional stock; or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">maintain their proportionate ownership interest. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common stock does not have cumulative
voting rights. Holders of shares of the common stock are not required to make additional capital contributions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Transfer Agent and
Registrar</i>. Computershare Trust Company, N.A. is transfer agent and registrar for the common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the
NASDAQ Capital Market under the symbol &#147;AVEO&#148;. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Preferred Stock </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are authorized to issue &#147;blank check&#148; preferred stock, which may be issued in one or more series upon authorization of our board
of directors. Our board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of
preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be
listed. Under the certificate of incorporation, the number of authorized preferred stock may be increased or decreased (but not below the number of shares outstanding) by the affirmative vote of the holders of a majority of the voting power of the
capital stock entitled to vote thereon, voting as a single class. If the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not to seek stockholder approval. The specific terms of
any series of preferred stock offered pursuant to this prospectus will be described in the prospectus supplement relating to that series of preferred stock. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A series of our preferred stock could, depending on the terms of such series, impede the completion of a merger, tender offer or other
takeover attempt. Our board of directors will make any determination to issue preferred shares based upon its judgment as to the best interests of our stockholders. Our directors, in so acting, could issue preferred stock having terms that could
discourage an acquisition attempt through which an acquirer may be able to change the composition of our board of directors, including a tender offer or other transaction that some, or a majority, of our stockholders might believe to be in their
best interests or in which stockholders might receive a premium for their stock over the then-current market price of the stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preferred stock has the terms described below unless otherwise provided in the prospectus supplement relating to a particular series of preferred stock. You should read the prospectus supplement relating to the particular series of preferred stock
being offered for specific terms, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the designation and stated value per share of the preferred stock and the number of shares offered; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the amount of liquidation preference per share; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the price at which the preferred stock will be issued; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the dividend rate, or method of calculation of dividends, the dates on which dividends will be payable, whether dividends will be cumulative or noncumulative and, if cumulative, the dates from which dividends will
commence to accumulate; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any redemption or sinking fund provisions; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if other than the currency of the United States, the currency or currencies including composite currencies in which the preferred stock is denominated and/or in which payments will or may be payable; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any conversion provisions; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any other rights, preferences, privileges, limitations and restrictions on the preferred stock. </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock will, when issued, be fully paid and
<font style="white-space:nowrap">non-assessable.</font> Unless otherwise specified in the prospectus supplement, each series of preferred stock will rank equally as to dividends and liquidation rights in all respects with each other series of
preferred stock. The rights of holders of shares of each series of preferred stock will be subordinate to those of our general creditors. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may, at our option, with respect to any series of preferred stock, elect to offer fractional interests in shares of preferred stock, and
provide for the issuance of depositary receipts representing depositary shares, each of which will represent a fractional interest in a share of the series of preferred stock. The fractional interest will be specified in the prospectus supplement
relating to a particular series of preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Rank</i>. Unless otherwise specified in the prospectus supplement, the preferred
stock will, with respect to dividend rights and rights upon our liquidation, dissolution or winding up of our affairs, rank: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">senior to our common stock and to all equity securities ranking junior to such preferred stock with respect to dividend rights or rights upon our liquidation, dissolution or winding up of our affairs; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity securities rank on a parity with the preferred stock with respect to dividend rights or rights upon our
liquidation, dissolution or winding up of our affairs; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities rank senior to the preferred stock with respect to dividend rights or rights upon our liquidation,
dissolution or winding up of our affairs. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;equity securities&#148; does not include convertible debt
securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Dividends</i>. Holders of the preferred stock of each series will be entitled to receive, when, as and if declared by our
board of directors, cash dividends at such rates and on such dates described in the prospectus supplement. Different series of preferred stock may be entitled to dividends at different rates or based on different methods of calculation. The dividend
rate may be fixed or variable or both. Dividends will be payable to the holders of record as they appear on our stock books on record dates fixed by our board of directors, as specified in the applicable prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends on any series of preferred stock may be cumulative or noncumulative, as described in the applicable prospectus supplement. If our
board of directors does not declare a dividend payable on a dividend payment date on any series of noncumulative preferred stock, then the holders of that noncumulative preferred stock will have no right to receive a dividend for that dividend
payment date, and we will have no obligation to pay the dividend accrued for that period, whether or not dividends on that series are declared payable on any future dividend payment dates. Dividends on any series of cumulative preferred stock will
accrue from the date we initially issue shares of such series or such other date specified in the applicable prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No
dividends may be declared or paid or funds set apart for the payment of any dividends on any parity securities unless full dividends have been paid or set apart for payment on the preferred stock. If full dividends are not paid, the preferred stock
will share dividends pro rata with the parity securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dividends may be declared or paid or funds set apart for the payment of
dividends on any junior securities unless full dividends for all dividend periods terminating on or prior to the date of the declaration or payment will have been paid or declared and a sum sufficient for the payment set apart for payment on the
preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Liquidation Preference</i>. Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs,
then, before we make any distribution or payment to the holders of any common stock or any other class or series of our capital stock ranking junior to the preferred stock in the distribution of assets upon any
</p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liquidation, dissolution or winding up of our affairs, the holders of each series of preferred stock shall be entitled to receive out of assets legally available for distribution to stockholders,
liquidating distributions in the amount of the liquidation preference per share set forth in the prospectus supplement, plus any accrued and unpaid dividends thereon. Such dividends will not include any accumulation in respect of unpaid
noncumulative dividends for prior dividend periods. Unless otherwise specified in the prospectus supplement, after payment of the full amount of their liquidating distributions, the holders of preferred stock will have no right or claim to any of
our remaining assets. Upon any such voluntary or involuntary liquidation, dissolution or winding up, if our available assets are insufficient to pay the amount of the liquidating distributions on all outstanding preferred stock and the corresponding
amounts payable on all other classes or series of our capital stock ranking on parity with the preferred stock and all other such classes or series of shares of capital stock ranking on parity with the preferred stock in the distribution of assets,
then the holders of the preferred stock and all other such classes or series of capital stock will share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be entitled. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any such liquidation, dissolution or winding up and if we have made liquidating distributions in full to all holders of preferred stock,
we will distribute our remaining assets among the holders of any other classes or series of capital stock ranking junior to the preferred stock according to their respective rights and preferences and, in each case, according to their respective
number of shares. For such purposes, our consolidation or merger with or into any other corporation, trust or entity, or the sale, lease or conveyance of all or substantially all of our property or assets will not be deemed to constitute a
liquidation, dissolution or winding up of our affairs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Redemption</i>. If so provided in the applicable prospectus supplement, the
preferred stock will be subject to mandatory redemption or redemption at our option, as a whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a series of preferred stock that is subject to mandatory redemption will specify the number of shares of
preferred stock that shall be redeemed by us in each year commencing after a date to be specified, at a redemption price per share to be specified, together with an amount equal to all accrued and unpaid dividends thereon to the date of redemption.
Unless the shares have a cumulative dividend, such accrued dividends will not include any accumulation in respect of unpaid dividends for prior dividend periods. We may pay the redemption price in cash or other property, as specified in the
applicable prospectus supplement. If the redemption price for preferred stock of any series is payable only from the net proceeds of the issuance of shares of our capital stock, the terms of such preferred stock may provide that, if no such shares
of our capital stock shall have been issued or to the extent the net proceeds from any issuance are insufficient to pay in full the aggregate redemption price then due, such preferred stock shall automatically and mandatorily be converted into the
applicable shares of our capital stock pursuant to conversion provisions specified in the applicable prospectus supplement. Notwithstanding the foregoing, we will not redeem any preferred stock of a series unless: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously declare and pay or set aside funds to pay full cumulative dividends on the preferred stock for all past
dividend periods and the then current dividend period; or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if such series of preferred stock does not have a cumulative dividend, we have declared and paid or contemporaneously declare and pay or set aside funds to pay full dividends for the then current dividend period.
</td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we will not acquire any preferred stock of a series unless: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if that series of preferred stock has a cumulative dividend, we have declared and paid or contemporaneously declare and pay or set aside funds to pay full cumulative dividends on all outstanding shares of such series of
preferred stock for all past dividend periods and the then current dividend period; or </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if that series of preferred stock does not have a cumulative dividend, we have declared and paid or contemporaneously declare and pay or set aside funds to pay full dividends on the preferred stock of such series for
the then current dividend period. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, at any time we may purchase or acquire preferred stock of that series
(1)&#160;pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding preferred stock of such series or (2)&#160;by conversion into or exchange for shares of our capital stock ranking junior to the preferred stock of
such series as to dividends and upon liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If fewer than all of the outstanding shares of preferred stock of any series are to be
redeemed, we will determine the number of shares that may be redeemed pro rata from the holders of record of such shares in proportion to the number of such shares held or for which redemption is requested by such holder or by any other equitable
manner that we determine. Such determination will reflect adjustments to avoid redemption of fractional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise
specified in the prospectus supplement, we will mail notice of redemption at least 30 days but not more than 60 days before the redemption date to each holder of record of preferred stock to be redeemed at the address shown on our stock transfer
books. Each notice shall state: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the redemption date; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the number of shares and series of preferred stock to be redeemed; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the redemption price; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the place or places where certificates for such preferred stock are to be surrendered for payment of the redemption price; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">that dividends on the shares to be redeemed will cease to accrue on such redemption date; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the date on which the holder&#146;s conversion rights, if any, as to such shares shall terminate; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the specific number of shares to be redeemed from each such holder if fewer than all the shares of any series are to be redeemed. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If notice of redemption has been given and we have set aside the funds necessary for such redemption in trust for the benefit of the holders
of any shares called for redemption, then from and after the redemption date, dividends will cease to accrue on such shares, and all rights of the holders of such shares will terminate, except the right to receive the redemption price. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Voting Rights</i>. Holders of preferred stock will not have any voting rights, except as required by law or as indicated in the applicable
prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided for under the terms of any series of preferred stock, no consent or vote of the holders
of shares of preferred stock or any series thereof shall be required for any amendment to our certificate of incorporation that would increase the number of authorized shares of preferred stock or the number of authorized shares of any series
thereof or decrease the number of authorized shares of preferred stock or the number of authorized shares of any series thereof (but not below the number of authorized shares of preferred stock or such series, as the case may be, then outstanding).
</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Conversion Rights</i>. The terms and conditions, if any, upon which any series of preferred stock is convertible into our common stock
will be set forth in the applicable prospectus supplement relating thereto. Such terms will include the number of shares of common stock into which the shares of preferred stock are convertible, the conversion price, rate or manner of calculation
thereof, the conversion period, provisions as to whether conversion will be at our option or at the option of the holders of the preferred stock, the events requiring an adjustment of the conversion price and provisions affecting conversion in the
event of the redemption. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Transfer Agent and Registrar</i>. The transfer agent and registrar for the preferred
stock will be set forth in the applicable prospectus supplement. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Effects of Authorized but Unissued Stock </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to
any limitations imposed by the listing standards of the NASDAQ Capital Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and
unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. In addition, if we issue preferred stock, the issuance could
adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. </p>
<p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><b>Provisions of Our Certificate of Incorporation and <font style="white-space:nowrap">By-laws</font> and Delaware Law That May Have
Anti-Takeover Effects </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Board of Directors</i>. We do not have a classified board of directors. All of our directors are elected
annually. The number of directors comprising our board of directors is fixed from time to time by the board of directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Removal of
Directors by Stockholders</i>. Members of our board of directors may be removed from office at any time with or without cause by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote at an election of
directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Stockholder Nomination of Directors</i>. Our <font style="white-space:nowrap">by-laws</font> provide that a stockholder
must notify us in writing of any stockholder nomination of a director not earlier than the close of business on the 120th day, and not later than the close of business on the 90th day prior to the first anniversary of the preceding year&#146;s
annual meeting; provided, that, in the case of the annual meeting of stockholders, if the date of the annual meeting is more than 20 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so
delivered not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of business on the later of (x)&#160;the 90th day prior to such annual meeting and (y)&#160;the 10th day
following the day on which public announcement of the date of such annual meeting is first made by us. Our <font style="white-space:nowrap">by-laws</font> also provide that, subject to certain limitations, if a stockholder (or a qualified
representative of the stockholder) does not appear at a meeting of stockholders to present a nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by us. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Action By Written Consent</i>. Our certificate of incorporation and our <font style="white-space:nowrap">by-laws</font> provide that our
stockholders may not act by written consent and may only act at duly called meetings of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Delaware Business Combination
Statute.</i> Section&#160;203 of the General Corporation Law of the State of Delaware, which we refer to as the DGCL, is applicable to us. Section&#160;203 of the DGCL restricts some types of transactions and business combinations between a
corporation and a 15% stockholder. A 15% stockholder is generally considered by Section&#160;203 to be a person owning 15% or more of the corporation&#146;s outstanding voting stock. Section&#160;203 refers to a 15% stockholder as an
&#147;interested stockholder.&#148; Section&#160;203 restricts these transactions for a period of three years from the date the stockholder acquires 15% or more of our outstanding voting stock. With some exceptions, unless the transaction is
approved by the board of directors and the holders of at least <font style="white-space:nowrap">two-thirds</font> of the outstanding voting stock of the corporation, Section&#160;203 prohibits significant business transactions such as: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">a merger with, disposition of significant assets to or receipt of disproportionate financial benefits by the interested stockholder, and </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any other transaction that would increase the interested stockholder&#146;s proportionate ownership of any class or series of our capital stock. </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares held by the interested stockholder are not counted as outstanding when
calculating the <font style="white-space:nowrap">two-thirds</font> of the outstanding voting stock needed for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prohibition
against these transactions does not apply if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">prior to the time that any stockholder became an interested stockholder, the board of directors approved either the business combination or the transaction in which such stockholder acquired 15% or more of our
outstanding voting stock, or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the interested stockholder owns at least 85% of our outstanding voting stock as a result of a transaction in which such stockholder acquired 15% or more of our outstanding voting stock. Shares held by persons who are
both directors and officers or by some types of employee stock plans are not counted as outstanding when making this calculation. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Super-Majority Voting.</i> The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter
is required to amend a corporation&#146;s certificate of incorporation or <font style="white-space:nowrap">by-laws,</font> unless a corporation&#146;s certificate of incorporation or <font style="white-space:nowrap">by-laws,</font> as the case may
be, requires a greater percentage. Our <font style="white-space:nowrap">by-laws</font> may be amended or repealed by a majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our
stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors is
required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described in this paragraph. </p>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Directors&#146; Liability </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the
DGCL. Our certificate of incorporation provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director. However, these provisions do not eliminate or
limit the liability of any of our directors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">for any breach of their duty of loyalty to us or our stockholders; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">for voting or assenting to unlawful payments of dividends or other distributions; or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">for any transaction from which the director derived an improper personal benefit. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act or failure to act, or any cause of action, suit or claim that would accrue or arise prior to any amendment or repeal or
adoption of an inconsistent provision. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent
permitted by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our certificate of incorporation provides that we must indemnify our directors and officers and we
must advance expenses, including attorneys&#146; fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_9"></a>DESCRIPTION OF DEBT SECURITIES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer debt securities which may be senior or subordinated. We refer to the senior debt securities and the subordinated debt securities
collectively as debt securities. The following description summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities and the extent, if any, to which the general provisions
summarized below apply to any series of debt securities in the prospectus supplement relating to the series and any applicable free writing prospectus that we authorize to be delivered. When we refer to &#147;we,&#148; &#147;our,&#148;
&#147;us,&#148; &#147;AVEO,&#148; and &#147;the Company,&#148; in this section, we mean AVEO Pharmaceuticals, Inc., excluding, unless the context otherwise requires or as otherwise expressly stated, our subsidiaries. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue senior debt securities from time to time, in one or more series under a senior indenture to be entered into between us and a
senior trustee to be named in a prospectus supplement, which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under a subordinated indenture to be entered into between us and a
subordinated trustee to be named in a prospectus supplement, which we refer to as the subordinated trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to the registration statement of which this prospectus forms a
part. The senior indenture and the subordinated indenture are referred to individually as an indenture and together as the indentures and the senior trustee and the subordinated trustee are referred to individually as a trustee and together as the
trustees. This section summarizes some of the provisions of the indentures and is qualified in its entirety by the specific text of the indentures, including definitions of terms used in the indentures. Wherever we refer to particular sections of,
or defined terms in, the indentures, those sections or defined terms are incorporated by reference in this prospectus or the applicable prospectus supplement. You should review the indentures that are filed as exhibits to the registration statement
of which this prospectus forms a part for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither indenture will limit the amount of debt securities that we may
issue. The applicable indenture will provide that debt securities may be issued up to an aggregate principal amount authorized from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined by
reference to an index. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>General </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The senior debt securities will constitute our unsecured and unsubordinated general obligations and will rank equally in right of payment with
our other unsecured and unsubordinated obligations. The subordinated debt securities will constitute our unsecured and subordinated general obligations and will be junior in right of payment to our senior indebtedness (including senior debt
securities), as described under the heading &#147;&#151;Certain Terms of the Subordinated Debt Securities&#151;Subordination.&#148; The debt securities will be structurally subordinated to all existing and future indebtedness and other liabilities
of our subsidiaries unless such subsidiaries expressly guarantee such debt securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be our unsecured
obligations. Any secured debt or other secured obligations will be effectively senior to the debt securities to the extent of the value of the assets securing such debt or other obligations. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and/or free writing prospectus will include any additional or different terms of the debt securities of
any series being offered, including the following terms: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the title and type of the debt securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the debt securities will be senior or subordinated debt securities, and, with respect to any subordinated debt securities the terms on which they are subordinated; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the initial aggregate principal amount of the debt securities; </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the price or prices at which we will sell the debt securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the maturity date or dates of the debt securities and the right, if any, to extend such date or dates; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the rate or rates, if any, at which the debt securities will bear interest, or the method of determining such rate or rates; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the date or dates from which such interest will accrue, the interest payment dates on which such interest will be payable or the method of determination of such dates; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the right, if any, to extend the interest payment periods and the duration of that extension; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the manner of paying principal and interest and the place or places where principal and interest will be payable; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">provisions for a sinking fund, purchase fund or other analogous fund, if any; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any redemption dates, prices, obligations and restrictions on the debt securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the currency, currencies or currency units in which the debt securities will be denominated and the currency, currencies or currency units in which principal and interest, if any, on the debt securities may be payable;
</td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any conversion or exchange features of the debt securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the debt securities will be subject to the defeasance provisions in the indenture; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the debt securities will be issued in definitive or global form or in definitive form only upon satisfaction of certain conditions; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the debt securities will be guaranteed as to payment or performance; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any special tax implications of the debt securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any events of defaults or covenants in addition to or in lieu of those set forth in the indenture; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any other material terms of the debt securities. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we refer to &#147;principal&#148; in
this section with reference to the debt securities, we are also referring to &#147;premium, if any.&#148; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time,
without notice to or the consent of the holders of any series of debt securities, create and issue further debt securities of any such series ranking equally with the debt securities of such series in all respects (or in all respects other than
(1)&#160;the payment of interest accruing prior to the issue date of such further debt securities or (2)&#160;the first payment of interest following the issue date of such further debt securities). Such further debt securities may be consolidated
and form a single series with the debt securities of such series and have the same terms as to status, redemption or otherwise as the debt securities of such series. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may present debt securities for exchange and you may present debt securities for transfer in the manner, at the places and subject to the
restrictions set forth in the debt securities and the applicable prospectus supplement. We will provide you those services without charge, although you may have to pay any tax or other governmental charge payable in connection with any exchange or
transfer, as set forth in the indenture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities may bear interest at a fixed rate or a floating rate. Debt securities bearing no
interest or interest at a rate that at the time of issuance is below the prevailing market rate (original issue discount securities) may be sold at a discount below their stated principal amount. U.S. federal income tax considerations applicable to
any such discounted debt securities or to certain debt securities issued at par which are treated as having been issued at a discount for U.S. federal income tax purposes will be described in the applicable prospectus supplement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities with the principal amount payable on any principal payment
date, or the amount of interest payable on any interest payment date, to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. You may receive a payment of principal on
any principal payment date, or a payment of interest on any interest payment date, that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending on the value on such dates of the applicable
currency, security or basket of securities, commodity or index. Information as to the methods for determining the amount of principal or interest payable on any date, the currencies, securities or baskets of securities, commodities or indices to
which the amount payable on such date is linked and certain related tax considerations will be set forth in the applicable prospectus supplement. </p>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Certain Terms of the Senior Debt Securities </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Covenants. </i>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt securities, the
senior debt securities will not contain any financial or restrictive covenants, including covenants restricting either us or any of our subsidiaries from incurring, issuing, assuming or guaranteeing any indebtedness secured by a lien on any of our
or our subsidiaries&#146; property or capital stock, or restricting either us or any of our subsidiaries from entering into sale and leaseback transactions. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Consolidation, Merger and Sale of Assets. </i>Unless we indicate otherwise in a prospectus supplement with respect to a particular series
of senior debt securities, we may not consolidate with or merge into any other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to any person,
in either case, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the successor entity, if any, is a U.S. corporation, limited liability company, partnership or trust; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the successor entity assumes our obligations on the senior debt securities and under the senior indenture; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">we have delivered to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating that the consolidation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in
connection with such transaction, such supplemental indenture, comply with the senior indenture and all conditions precedent provided for in the senior indenture relating to such transaction have been complied with. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the bullets above do not apply (1)&#160;to our consolidation with or merging into one of our affiliates, if our board of
directors determines in good faith that the purpose of the consolidation or merger is principally to change our state of incorporation or our form of organization to another form or (2)&#160;if we merge with or into a single direct or indirect
wholly-owned subsidiary of ours. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The surviving business entity will succeed to, and be substituted for, us under the senior indenture and the senior debt
securities and, except in the case of a lease, we shall be released from all obligations under the senior indenture and the senior debt securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><i>No
Protection in the Event of a Change in Control. </i>Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt securities, the senior debt securities will not contain any provisions that may afford
holders of the senior debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control). </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Events of Default. </i>Unless we indicate otherwise in a prospectus supplement with
respect to a particular series of senior debt securities, the following are events of default under the senior indenture with respect to senior debt securities of each series: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">failure to pay interest on any senior debt securities of such series when due and payable, if that default continues for a period of 30 days (or such other period as may be specified for such series); </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">failure to pay principal on the senior debt securities of such series when due and payable whether at maturity, upon redemption, by declaration or otherwise (and, if specified for such series, the continuance of such
failure for a specified period); </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">default in the performance of or breach of any of our covenants or agreements in the senior indenture applicable to senior debt securities of such series, other than a covenant breach which is specifically dealt with
elsewhere in the senior indenture, and that default or breach continues for a period of 90 days after we receive written notice from the trustee or from the holders of 25% or more in aggregate principal amount of the senior debt securities of such
series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">certain events of bankruptcy or insolvency, whether or not voluntary; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any other event of default provided for in such series of senior debt securities as may be specified in the applicable prospectus supplement. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The default by us under any other debt, including any other series of debt securities, is not a default under the senior indenture. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default other than an event of default specified in the fourth bullet point above occurs with respect to a series of senior
debt securities and is continuing under the senior indenture, then, and in each such case, either the trustee or the holders of not less than 25% in aggregate principal amount of such series then outstanding under the senior indenture (each such
series voting as a separate class) by written notice to us and to the trustee, if such notice is given by the holders, may, and the trustee at the request of such holders shall, declare the principal amount of and accrued interest on such series of
senior debt securities to be immediately due and payable, and upon this declaration, the same shall become immediately due and payable. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default specified in the fourth bullet point above occurs and is continuing, the entire principal amount of and accrued
interest on each series of senior debt securities then outstanding shall automatically become immediately due and payable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise specified in the prospectus supplement relating to a series of senior debt securities originally issued at a discount, the amount due upon acceleration shall include only the original issue price of the senior debt securities, the amount
of original issue discount accrued to the date of acceleration and accrued interest, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon certain conditions, declarations of
acceleration may be rescinded and annulled and past defaults may be waived by the holders of a majority in aggregate principal amount of all the senior debt securities of such series affected by the default, each series voting as a separate class.
Furthermore, subject to various provisions in the senior indenture, the holders of a majority in aggregate principal amount of a series of senior debt securities, by notice to the trustee, may waive a continuing default or event of default with
respect to such senior debt securities and its consequences, except a default in the payment of principal of or interest on such senior debt securities (other than any such default in payment resulting solely from an acceleration of the senior debt
securities) or in respect of a covenant or provision of the senior indenture which cannot be modified or amended without the consent of the holders of each such senior debt security. Upon any such waiver, such default shall cease to exist, and any
event of default with respect to such senior debt securities shall be deemed to have been cured, for every purpose of the senior indenture; but no such waiver shall extend to any subsequent or other default or event of default or impair any right
consequent thereto. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of a series of senior debt
securities may direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee with respect to such senior debt securities. However, the trustee may
refuse to follow any direction that conflicts with law or the senior indenture, that may involve the trustee in personal liability or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of such series of
senior debt securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent with any such direction received from holders of such series of senior debt securities. A holder may not pursue
any remedy with respect to the senior indenture or any series of senior debt securities unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the holder gives the trustee written notice of a continuing event of default; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the holders of at least 25% in aggregate principal amount of such series of senior debt securities make a written request to the trustee to pursue the remedy in respect of such event of default; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the requesting holder or holders offer the trustee indemnity satisfactory to the trustee against any costs, liability or expense; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the trustee does not comply with the request within 60 days after receipt of the request and the offer of indemnity; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">during such <font style="white-space:nowrap">60-day</font> period, the holders of a majority in aggregate principal amount of such series of senior debt securities do not give the trustee a direction that is
inconsistent with the request. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations, however, do not apply to the right of any holder of a senior debt
security of any affected series to receive payment of the principal of and interest on such senior debt security in accordance with the terms of such debt security, or to bring suit for the enforcement of any such payment in accordance with the
terms of such debt security, on or after the due date for the senior debt securities, which right shall not be impaired or affected without the consent of the holder. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The senior indenture requires certain of our officers to certify, on or before a fixed date in each year in which any senior debt security is
outstanding, as to their knowledge of our compliance with all covenants, agreements and conditions under the senior indenture. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Satisfaction and Discharge</i>. We can satisfy and discharge our obligations to holders of any series of debt securities if: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">we have paid or caused to be paid the principal of and interest on all senior debt securities of such series (with certain limited exceptions) when due and payable; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">we deliver to the senior trustee for cancellation all senior debt securities of such series theretofore authenticated under the senior indenture (with certain limited exceptions); or </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all senior debt securities of such series have become due and payable or will become due and payable within one year (or are to be called for redemption within one year under arrangements satisfactory to the senior
trustee) and we deposit in trust an amount of cash or a combination of cash and U.S. government or U.S. government agency obligations (or in the case of senior debt securities denominated in a foreign currency, foreign government securities or
foreign government agency securities) sufficient to make interest, principal and any other payments on the debt securities of that series on their various due dates; </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and if, in any such case, we also pay or cause to be paid all other sums payable under the senior indenture, as and when the same shall be due and payable and
we deliver to the senior trustee an officer&#146;s certificate and an opinion of counsel, each stating that these conditions have been satisfied. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current U.S. federal income tax law, the deposit and our legal release from the debt securities would be treated as though we took back
your debt securities and gave you your share of the cash and debt securities or </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities you give back to us. Purchasers of the debt securities should consult their own advisers with
respect to the tax consequences to them of such deposit and discharge, including the applicability and effect of tax laws other than the U.S. federal income tax law. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Defeasance.</i> Unless the applicable prospectus supplement provides otherwise, the following discussion of legal defeasance and covenant
defeasance will apply to any series of debt securities issued under the indentures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Legal Defeasance</i>. We can legally release
ourselves from any payment or other obligations on the debt securities of any series, called &#147;legal defeasance&#148;, if certain conditions are met, including the following: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">We deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the same series cash or a combination of cash and U.S. government or U.S. government agency obligations (or, in
the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that will generate enough cash to make interest, principal and any other payments on the debt securities of that
series on their various due dates. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">There is a change in current U.S. federal income tax law or a U.S. Internal Revenue Service ruling that lets us make the above deposit without causing you to be taxed on the debt securities any differently than if we
did not make the deposit and instead repaid the debt securities ourselves when due. Under current U.S. federal income tax law, the deposit and our legal release from the debt securities would be treated as though we took back your debt securities
and gave you your share of the cash and debt securities or bonds deposited in trust. In that event, you could recognize gain or loss on the debt securities you give back to us. </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">We deliver to the trustee a legal opinion of our counsel confirming the tax law change or ruling described above. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we accomplish legal defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the debt
securities. You could not look to us for repayment in the event of any shortfall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Covenant Defeasance</i>. Without any change in
current U.S. federal tax law, we can make the same type of deposit described above and be released from some of the covenants in the debt securities, called &#147;covenant defeasance&#148;. In that event, you would lose the protection of those
covenants but would gain the protection of having money and securities set aside in trust to repay the debt securities. In order to achieve covenant defeasance, we must do the following (among other things): </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">We must deposit in trust for your benefit and the benefit of all other direct holders of the debt securities of the same series cash or a combination of cash and U.S. government or U.S. government agency obligations
(or, in the case of senior debt securities denominated in a foreign currency, foreign government or foreign government agency obligations) that will generate enough cash to make interest, principal and any other payments on the debt securities of
that series on their various due dates. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">We must deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income tax law we may make the above deposit without causing you to be taxed on the debt securities any
differently than if we did not make the deposit and instead repaid the debt securities ourselves when due. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we accomplish
covenant defeasance, you could still look to us for repayment of the debt securities if there were a shortfall in the trust deposit. In fact, if one of the events of default occurred (such as our bankruptcy) and the debt securities become
immediately due and payable, there may be such a shortfall. Depending on the events causing the default, you may not be able to obtain payment of the shortfall. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Modification and Waiver</i>. We and the trustee may amend or supplement the senior
indenture or the senior debt securities of any series without the consent of any holder: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or more series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to evidence the succession of a corporation, limited liability company, partnership or trust to us, and the assumption by such successor of our covenants, agreements and obligations under the senior indenture or to
otherwise comply with the covenant relating to mergers, consolidations and sales of assets; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to comply with requirements of the SEC in order to effect or maintain the qualification of the senior indenture under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the holders, and to make the occurrence, or the occurrence and continuance, of a default in any such additional
covenants, restrictions, conditions or provisions an event of default; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to cure any ambiguity, defect or inconsistency in the senior indenture or in any supplemental indenture or to conform the senior indenture or the senior debt securities to the description of senior debt securities of
such series set forth in this prospectus or any applicable prospectus supplement; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to provide for or add guarantors with respect to the senior debt securities of any series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to establish the form or forms or terms of the senior debt securities as permitted by the senior indenture; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to evidence and provide for the acceptance of appointment under the senior indenture by a successor trustee, or to make such changes as shall be necessary to provide for or facilitate the administration of the trusts in
the senior indenture by more than one trustee; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to add to, change or eliminate any of the provisions of the senior indenture in respect of one or more series of senior debt securities, provided that any such addition, change or elimination shall (a)&#160;neither (1)
apply to any senior debt security of any series created prior to the execution of such supplemental indenture and entitled to the benefit of such provision nor (2)&#160;modify the rights of the holder of any such senior debt security with respect to
such provision or (b)&#160;become effective only when there is no senior debt security described in clause (a)(1) outstanding; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to make any change to the senior debt securities of any series so long as no senior debt securities of such series are outstanding; or </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">to make any change that does not adversely affect the rights of any holder in any material respect. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other amendments and modifications of the senior indenture or the senior debt securities issued may be made, and our compliance with any
provision of the senior indenture with respect to any series of senior debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount of the outstanding senior debt securities of each series affected
by the amendment or modification (voting as separate series); provided, however, that each affected holder must consent to any modification, amendment or waiver that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">extends the final maturity of any senior debt securities of such series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">reduces the principal amount of any senior debt securities of such series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">reduces the rate, or extends the time for payment of, interest on any senior debt securities of such series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">reduces the amount payable upon the redemption of any senior debt securities of such series; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">changes the currency of payment of principal of or interest on any senior debt securities of such series; </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">reduces the principal amount of original issue discount securities payable upon acceleration of maturity or the amount provable in bankruptcy; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">waives a continuing default in the payment of principal of or interest on the senior debt securities (other than any such default in payment resulting solely from an acceleration of the senior debt securities);
</td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">changes the provisions relating to the waiver of past defaults or impairs the right of holders to receive payment or to institute suit for the enforcement of any payment or conversion of any senior debt securities of
such series on or after the due date therefor; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">modifies any of the provisions of these restrictions on amendments and modifications, except to increase any required percentage or to provide that certain other provisions cannot be modified or waived without the
consent of the holder of each senior debt security of such series affected by the modification; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">adversely affects the right to convert or exchange senior debt securities into common stock or other property in accordance with the terms of the senior debt securities; or </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">reduces the above-stated percentage of outstanding senior debt securities of such series whose holders must consent to a supplemental indenture or modifies, amends or waives certain provisions of or defaults under the
senior indenture. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall not be necessary for the holders to approve the particular form of any proposed amendment,
supplement or waiver, but it shall be sufficient if the holders&#146; consent approves the substance thereof. After an amendment, supplement or waiver of the senior indenture in accordance with the provisions described in this section becomes
effective, the trustee must give to the holders affected thereby certain notice briefly describing the amendment, supplement or waiver. Any failure by the trustee to give such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any such amendment, supplemental indenture or waiver. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>No Personal Liability of Incorporators, Stockholders,
Officers, Directors</i>. The senior indenture provides that no recourse shall be had under any obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any of the senior debt securities or because of the
creation of any indebtedness represented thereby, against any of our incorporators, stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any law, statute or constitutional provision or
by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each holder, by accepting the senior debt securities, waives and releases all such liability. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Concerning the Trustee</i>. The senior indenture provides that, except during the continuance of an event of default, the trustee will not
be liable except for the performance of such duties as are specifically set forth in the senior indenture. If an event of default has occurred and is continuing, the trustee will exercise such rights and powers vested in it under the senior
indenture and will use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person&#146;s own affairs. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The senior indenture and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on the rights of the
trustee thereunder, should it become a creditor of ours or any of our subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or otherwise. The trustee is
permitted to engage in other transactions, provided that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may have normal banking relationships with the senior trustee in the ordinary course of business. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Unclaimed Funds</i>. All funds deposited with the trustee or any paying agent for the payment of principal, premium, interest or additional
amounts in respect of the senior debt securities that remain unclaimed for two </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years after the date upon which such amounts became due and payable will be repaid to us. Thereafter, any right of any holder of senior debt securities to such funds shall be enforceable only
against us, and the trustee and paying agents will have no liability therefor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Governing Law</i>. The senior indenture and the senior
debt securities will be governed by, and construed in accordance with, the internal laws of the State of New York. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Certain Terms of
the Subordinated Debt Securities </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the terms of the subordinated indenture and subordinated debt securities relating to
subordination or otherwise as described in the prospectus supplement relating to a particular series of subordinated debt securities, the terms of the subordinated indenture and subordinated debt securities are identical in all material respects to
the terms of the senior indenture and senior debt securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional or different subordination terms may be specified in the
prospectus supplement applicable to a particular series. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><i>Subordination</i>. The indebtedness evidenced by the subordinated debt
securities is subordinate to the prior payment in full of all of our senior indebtedness, as defined in the subordinated indenture. During the continuance beyond any applicable grace period of any default in the payment of principal, premium,
interest or any other payment due on any of our senior indebtedness, we may not make any payment of principal of or interest on the subordinated debt securities (except for certain sinking fund payments). In addition, upon any payment or
distribution of our assets upon any dissolution, <font style="white-space:nowrap">winding-up,</font> liquidation or reorganization, the payment of the principal of and interest on the subordinated debt securities will be subordinated to the extent
provided in the subordinated indenture in right of payment to the prior payment in full of all our senior indebtedness. Because of this subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt securities may receive
less, ratably, than holders of our senior indebtedness. The subordination provisions do not prevent the occurrence of an event of default under the subordinated indenture. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;senior indebtedness&#148; of a person means with respect to such person the principal of, premium, if any, interest on, and any
other payment due pursuant to any of the following, whether outstanding on the date of the subordinated indenture or incurred by that person in the future: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all of the indebtedness of that person for money borrowed; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all of the indebtedness of that person evidenced by notes, debentures, bonds or other securities sold by that person for money; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all of the lease obligations that are capitalized on the books of that person in accordance with generally accepted accounting principles; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all indebtedness of others of the kinds described in the first two bullet points above and all lease obligations of others of the kind described in the third bullet point above that the person, in any manner, assumes or
guarantees or that the person in effect guarantees through an agreement to purchase, whether that agreement is contingent or otherwise; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all renewals, extensions or refundings of indebtedness of the kinds described in the first, second or fourth bullet point above and all renewals or extensions of leases of the kinds described in the third or fourth
bullet point above; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">unless, in the case of any particular indebtedness, renewal, extension or refunding, the instrument
creating or evidencing it or the assumption or guarantee relating to it expressly provides that such indebtedness, renewal, extension or refunding is not superior in right of payment to the subordinated debt securities. Our senior debt securities
constitute senior indebtedness for purposes of the subordinated indenture. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_10"></a>DESCRIPTION OF WARRANTS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase common stock, preferred stock or debt securities. We may offer warrants separately or together with one or
more additional warrants, common stock, preferred stock or debt securities, or any combination of those securities in the form of units, as described in the applicable prospectus supplement. If we issue warrants as part of a unit, the accompanying
prospectus supplement will specify whether those warrants may be separated from the other securities in the unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the following terms of any
warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the specific designation and aggregate number of, and the offering price at which we will issue, the warrants; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the currency or currency units in which the offering price, if any, and the exercise price are payable; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on
which you may exercise the warrants; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the warrants are to be sold separately or with other securities as parts of units; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">whether the warrants will be issued in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any
security included in that unit; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any applicable material U.S. federal income tax consequences; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the designation and terms of any equity securities purchasable upon exercise of the warrants; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon exercise of the warrants; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if applicable, the designation and terms of the preferred stock with which the warrants are issued and the number of warrants issued with each security; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if applicable, the date from and after which any warrants issued as part of a unit and the related debt securities, preferred stock, or common stock will be separately transferable; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the number of shares of common stock or preferred stock purchasable upon exercise of a warrant and the price at which those shares may be purchased; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">information with respect to book-entry procedures, if any; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the anti-dilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the warrants, if any; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any redemption or call provisions; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or exercise of the warrants. </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_11"></a>DESCRIPTION OF UNITS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other securities that may be offered under this prospectus, in any combination. The
following, together with the additional information we may include in the applicable prospectus supplement, summarizes the material terms and provisions of the units that we may offer under this prospectus. While the terms summarized below will
apply generally to any units we may offer, we will describe the particular terms of any series of units in more detail in the applicable prospectus supplement. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit
will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately at any time, or at any time
before a specified date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any applicable prospectus supplement will describe: </p>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the material terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any material provisions relating to the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any material provisions of the governing unit agreement that differ from those described above. </td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">25 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_12"></a>FORMS OF SECURITIES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security, unit and warrant will be represented either by a certificate issued in definitive form to a particular investor or by one
or more global securities representing the entire issuance of securities. Unless the applicable prospectus supplement provides otherwise, certificated securities in definitive form and global securities will be issued in registered form. Definitive
securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities
to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, units or warrants represented by these global securities. The depositary maintains a
computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below. </p>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Global Securities </b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
issue the debt securities, units and warrants in the form of one or more fully registered global securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that
depositary or nominee. In those cases, one or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by global securities.
Unless and until it is exchanged in whole for securities in definitive registered form, a global security may not be transferred except as a whole by and among the depositary for the global security, the nominees of the depositary or any successors
of the depositary or those nominees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If not described below, any specific terms of the depositary arrangement with respect to any
securities to be represented by a global security will be described in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a global security will be limited to persons, called participants, that have accounts with the depositary
or persons that may hold interests through participants. Upon the issuance of a global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal or face
amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a global
security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of
persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial
interests in global securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depositary, or its nominee, is the registered owner of a global security, that depositary
or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the global security for all purposes under the applicable indenture, warrant agreement or unit agreement. Except as described below,
owners of beneficial interests in a global security will not be entitled to have the securities represented by the global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in
definitive form and will not be considered the owners or holders of the securities under the applicable indenture, unit agreement or warrant agreement. Accordingly, each person owning a beneficial interest in a global security must rely on the
procedures of the depositary for that global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture, unit
agreement or warrant agreement. We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a global security desires to give or take any action that a holder is entitled to
give or take </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">26 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the applicable indenture, unit agreement or warrant agreement, the depositary for the global security would authorize the participants holding the relevant beneficial interests to give or
take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal, premium, if any, and interest payments on debt securities, and any payments to holders with respect to warrants or units,
represented by a global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the global security. None of us, or any trustee, warrant agent, unit
agent or other agent of ours, or any agent of any trustee, warrant agent or unit agent will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the global
security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the
depositary for any of the securities represented by a global security, upon receipt of any payment to holders of principal, premium, interest or other distribution of underlying securities or other property on that registered global security, will
immediately credit participants&#146; accounts in amounts proportionate to their respective beneficial interests in that global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial
interests in a global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or registered in &#147;street name,&#148;
and will be the responsibility of those participants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary for any of the securities represented by a global security is at
any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90 days, we
will issue securities in definitive form in exchange for the global security that had been held by the depositary. Any securities issued in definitive form in exchange for a global security will be registered in the name or names that the depositary
gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary&#146;s instructions will be based upon directions received by the depositary from participants with respect to
ownership of beneficial interests in the global security that had been held by the depositary. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_13"></a>PLAN OF DISTRIBUTION </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">through underwriters; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">through dealers; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">through agents; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">directly to purchasers; or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">through a combination of any of these methods of sale. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may issue the
securities as a dividend or distribution or in a subscription rights offering to our existing security holders. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in
the applicable prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such
offers. We will, in the prospectus supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts
basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
distribution of the securities may be effected from time to time in one or more transactions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">at a fixed price, or prices, which may be changed from time to time; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">at market prices prevailing at the time of sale; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">at prices related to such prevailing market prices; or </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">at negotiated prices. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of
the securities and any applicable restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will
describe the terms of the offering of the securities, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the name of the agent or any underwriters; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the public offering or purchase price and the proceeds we will receive from the sale of the securities; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any discounts and commissions to be allowed or <font style="white-space:nowrap">re-allowed</font> or paid to the agent or underwriters; </td></tr></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">all other items constituting underwriting compensation; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any discounts and commissions to be allowed or <font style="white-space:nowrap">re-allowed</font> or paid to dealers; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">any exchanges on which the securities will be listed. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are
utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement or other agreement with them at the time of sale to them, and we will set forth in the prospectus supplement
relating to such offering the names of the underwriters or agents and the terms of the related agreement with them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities in respect of which this prospectus is delivered, we will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such
dealer at the time of resale. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security holders,
we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby
underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Remarketing firms, agents,
underwriters, dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in
transactions with or perform services for us in the ordinary course of business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement,
we will authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the
prospectus supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement.
Institutions with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases
be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and
</td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td width="4%">&#160;</td>
<td align="left" valign="top" width="3%">&#149;</td>
<td valign="top" width="1%">&#160;</td>
<td align="left" valign="top">if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons
acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts. </td></tr></table>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing relationships with, engage
in other transactions with, and/or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in
any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases
previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels.
Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <font style="white-space:nowrap">15c6-1</font> of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an
underwriter in a firm commitment underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities.
Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to
settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market.
The securities may or may not be listed on a national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with the guidelines of the Financial Industry Regulatory Authority, or FINRA, the aggregate maximum discount, commission or
agency fees or other items constituting underwriting compensation to be received by any FINRA member or independent broker-dealer will not exceed 8% of the proceeds from any offering pursuant to this prospectus and any applicable prospectus
supplement. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_14"></a>LEGAL MATTERS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, the validity of the securities in respect of which this prospectus is being
delivered will be passed upon by Wilmer Cutler Pickering Hale and Dorr LLP, Boston, Massachusetts. </p> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="toc499409_15"></a>EXPERTS
</b></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of AVEO Pharmaceuticals, Inc. appearing in AVEO Pharmaceuticals Inc.&#146;s Annual Report <font style="white-space:nowrap">(Form&#160;10-K)&#160;for</font> the year ended December&#160;31, 2016, and the effectiveness of AVEO Pharmaceuticals Inc.&#146;s internal control over financial reporting as of December&#160;31, 2016, have been audited by
Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in its reports thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability to continue
as a going concern as described in Note 1 to the consolidated financial statements), which conclude, among other things, that AVEO Pharmaceuticals, Inc. did not maintain effective internal control over financial reporting as of December&#160;31,
2016, based on Internal Control&#151;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), because of the effects of the material weakness described therein, included therein, and
incorporated herein by reference. Such financial statements have been incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">31 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p>
<p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<p align="center" style="margin-top:0pt;margin-bottom:0pt">
<img alt="LOGO" src="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/g499409g70w65.jpg"/>
</p> <p align="center" style="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><b>$200,000,000 </b></p>
<p align="center" style="margin-top:36pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Common Stock </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Preferred
Stock </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Debt Securities </b></p>
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Warrants </b></p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman"><b>Units </b></p>
<p style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><b>PROSPECTUS </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><center>
<p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&#160;</p></center>
<p align="center" style="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2017 </b></p>
<p style="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p>
<p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>PART II </b></p>
<p align="center" style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>INFORMATION NOT REQUIRED IN PROSPECTUS </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Item&#160;14. Other Expenses of Issuance and Distribution. </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are estimates (except in the case of the SEC registration and FINRA fees) of the amount of fees and expenses to be incurred in
connection with the issuance and distribution of the offered securities, other than underwriting discounts and commissions. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="68%">
<tr>
<td width="80%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">24,900.00</td>
<td nowrap="" valign="bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving fees</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr bgcolor="#cceeff" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">&#160;</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td valign="bottom">&#160;&#160;</td>
<td valign="bottom">$</td>
<td align="right" valign="bottom">(1</td>
<td nowrap="" valign="bottom">)&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">(1)</td>
<td align="left" valign="top">These fees and expenses are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time. They will be reflected in the applicable prospectus supplement.
</td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Item&#160;15. Indemnification of Directors and Officers. </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the General Corporation Law of the State of Delaware, or the DGCL, provides, generally, that a corporation shall have the power to
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was
a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted
in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was
unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, <i>provided</i> that
such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to
the corporation, <i>provided</i> that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for
such expenses which such court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides, generally, that our certificate of incorporation may
contain a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, <i>provided</i> that such provision may not eliminate or limit
the liability of a director (i)&#160;for any breach of the director&#146;s duty of loyalty to the corporation or its shareholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of
law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. No such provision may eliminate or limit the liability of a director for any act or omission occurring
prior to the date when such provision became effective. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that we will indemnify each person who
was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of us) by reason of the fact that
he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-1 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons
being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by the Indemnitee or on his or her behalf in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed
to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement,
conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in, or not opposed to, our best
interests, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her conduct was unlawful. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party or threatened to be made a party to
any threatened, pending or completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has
agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken
or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal
therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such
person shall have been adjudged to be liable to us, unless and only to the extent that a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification for such expenses.
Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred by him or
her or on his or her behalf in connection therewith. If we don&#146;t assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy which covers certain liabilities of our directors and officers arising out of claims based on
acts or omissions in their capacities as directors or officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <font style="white-space:nowrap">non-employee</font>
directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities in their capacity as members of our board of directors. </p>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Item&#160;16. Exhibits. </b></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td></td>
<td valign="bottom" width="9%"></td>
<td width="88%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" valign="bottom"><b>Exhibit&#160;No.</b></td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" valign="bottom"><b>Description</b></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;1.1*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Underwriting Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312517252007/d601158dex31.htm">Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Quarterly
 Report on Form <font style="white-space:nowrap">10-Q</font> filed on August&#160;9, 2017 (File <font style="white-space:nowrap">No.&#160;001-34655))</font></a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.2</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="http://www.sec.gov/Archives/edgar/data/1325879/000119312510024516/dex35.htm">Second Amended and Restated <font style="white-space:nowrap">By-laws</font> of the Registrant (incorporated by reference to Exhibit 3.5 to the Registrant&#146;s
 Registration Statement on <font style="white-space:nowrap">S-1,</font> as amended, filed on February&#160;8, 2010 (File <font style="white-space:nowrap">No.&#160;333-163778))</font></a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.3</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex43.htm">Form of Senior Indenture</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.4</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex44.htm">Form of Subordinated Indenture</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.5</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex45.htm">Form of Senior Note</a></td></tr></table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-2 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<table align="center" border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td></td>
<td valign="bottom" width="10%"></td>
<td width="88%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" valign="bottom"><b>Exhibit&#160;No.</b></td>
<td valign="bottom">&#160;&#160;</td>
<td align="center" valign="bottom"><b>Description</b></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.6</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex46.htm">Form of Subordinated Note</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.7*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Warrant Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;4.8*</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">Form of Unit Agreement</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">&#160;&#160;5.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">12.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex121.htm">Calculation of Consolidated Ratios of Earnings to Fixed Charges and Consolidated Ratios of Earnings to Combined Fixed Charges and Preferred Stock Dividends</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">23.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex231.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm for the Registrant</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">23.2</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="https://www.sec.gov/Archives/edgar/data/0001325879/000119312517357512/d499409dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">24.1</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top"><a href="#sig">Powers of Attorney (included in the signature pages to the Registration Statement)</a></td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">25.1**</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">The Statement of Eligibility on Form <font style="white-space:nowrap">T-1</font> under the Trust Indenture Act of 1939, as amended, of the Trustee under the Senior Indenture</td></tr>
<tr style="font-size:1pt">
<td height="8"></td>
<td colspan="2" height="8"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td nowrap="" valign="top">25.2**</td>
<td valign="bottom">&#160;&#160;</td>
<td valign="top">The Statement of Eligibility on Form <font style="white-space:nowrap">T-1</font> under the Trust Indenture Act of 1939, as amended, of the Trustee under the Subordinated Indenture</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">*</td>
<td align="left" valign="top">To be filed by amendment or by a Current Report on Form <font style="white-space:nowrap">8-K.</font> </td></tr></table>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr style="page-break-inside:avoid">
<td align="left" valign="top" width="4%">**</td>
<td align="left" valign="top">To be filed pursuant to Section&#160;305(b)(2) of the Trust Indenture Act of 1939, as amended. </td></tr></table>
<p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><b>Item&#160;17. Undertakings. </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes: </p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended, or the Securities Act; </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not
previously disclosed in this registration statement or any material change to such information in this registration statement; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><i>provided</i>,
<i>however</i>, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the
Registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed
pursuant to Rule 424(b) that is part of this registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purposes of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial <i>bona fide</i>
offering thereof. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-3 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the
Securities Act to any purchaser: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) each
prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the
information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the
first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date
of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof;
<i>provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of
the registration statement or made in any such document immediately prior to such effective date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of
determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to
this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will
be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or
prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant; </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned
Registrant or its securities provided by or on behalf of the undersigned Registrant; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) any other communication that is an offer in
the offering made by the undersigned Registrant to the purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) That, for purposes of determining any liability under the
Securities Act, each filing of the Registrant&#146;s annual report pursuant to Section&#160;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&#160;15(d) of the
Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) That, insofar as indemnification for liabilities arising under the Securities Act may be
permitted to directors, officers and controlling persons of the Registrant pursuant to the indemnification provisions described </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-4 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
herein, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) That, for purposes of determining any liability under the Securities Act: </p>
<p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) the information omitted from the form of prospectus filed as part of the registration statement in reliance upon Rule 430A and contained in
the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it was declared effective; and </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof. </p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To file an application for the purpose of determining the eligibility of the trustee to act under subsection (a)&#160;of Section&#160;310
of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section&#160;305(b)(2) of the Trust Indenture Act. </p>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-5 </p>
</div></center>
<p style="page-break-before:always">
</p><hr align="CENTER" size="3" style="COLOR:#999999" width="100%"/>
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<center><div align="left" style="width:8.5in">
<p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b>SIGNATURES </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, or the Securities Act, the Registrant certifies that it has reasonable
grounds to believe that it meets all of the requirements for filing on Form <font style="white-space:nowrap">S-3</font> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
city of Cambridge, Commonwealth of Massachusetts, on November&#160;30, 2017. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div align="right">
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="40%">
<tr>
<td width="6%"></td>
<td valign="bottom" width="2%"></td>
<td width="92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td colspan="3" valign="top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AVEO PHARMACEUTICALS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</p></td>
<td valign="bottom">&#160;</td>
<td valign="bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bailey</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Michael Bailey</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="bottom"></td>
<td valign="bottom">&#160;</td>
<td valign="bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: President&#160;&amp; Chief Executive Officer</p></td></tr>
</table></div> <p align="center" style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><b><a name="sig"></a>SIGNATURES AND POWER OF ATTORNEY </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of AVEO Pharmaceuticals, Inc., hereby severally constitute and appoint Michael Bailey and Matthew
Dallas, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form <font style="white-space:nowrap">S-3</font> filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and any registration statement filed pursuant to Rule 462 under the Securities Act, in connection
with said Registration Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on
our behalf in our capacities as officers and directors to enable AVEO Pharmaceuticals, Inc. to comply with the provisions of the Securities Act, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that
said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" width="100%">
<tr>
<td width="37%"></td>
<td valign="bottom"></td>
<td width="43%"></td>
<td valign="bottom" width="1%"></td>
<td width="18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman"><b>Signature</b></p></td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman"><b>Title</b></p></td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="bottom"> <p align="center" style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><b>Date</b></p></td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bailey</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Bailey</p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top"> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director (<i>Principal Executive Officer</i>)</p></td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="top">November&#160;30, 2017</td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Dallas</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Matthew Dallas</p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top">Chief Financial Officer<br/>(<i>Principal</i> <i>Financial and Accounting Officer</i>)</td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="top">November&#160;30, 2017</td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kenneth M. Bate</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kenneth M. Bate</p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="top">November&#160;30, 2017</td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anthony B. Evnin</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anthony B. Evnin</p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="top">November&#160;30, 2017</td></tr>
<tr style="font-size:1pt">
<td height="16"></td>
<td colspan="2" height="16"></td>
<td colspan="2" height="16"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td valign="top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert C. Young</p>
<p align="center" style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert C. Young</p></td>
<td valign="bottom">&#160;</td>
<td align="center" valign="top">Director</td>
<td valign="bottom">&#160;</td>
<td align="center" nowrap="" valign="top">November&#160;30, 2017</td></tr>
</table>
<p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p align="center" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">II-6 </p>
</div></center>
</text>
</description></filename></sequence></type></document>
</body></html>